Browsing Tag
GLP-1 alternatives
2 posts
Is the next wave of obesity drugs moving beyond GLP-1? What Palatin, Rhythm, and Zealand are betting on
Explore how Palatin Technologies, Rhythm Pharmaceuticals, and Zealand Pharma are shifting obesity drug development beyond GLP-1 into MC4R and amylin pathways. Read on.
Which biotech companies are developing next-gen GLP-1 alternatives—and can they compete with Novo Nordisk and Eli Lilly by 2030?
Discover how biotech players like Viking, Structure, and Altimmune are developing next-gen GLP-1 drugs to challenge obesity leaders Novo Nordisk and Eli Lilly. Read more.